Drilldown: Medicines
Appearance
Medicines > onset
:
1–2 h
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
Peak anticoagulant effect 3-4 hours 
:
1–2 h
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
Peak anticoagulant effect 3-4 hours 
Use the filters below to narrow your results.
Beta Blocker (2) ·
Cardioselective (β1) (1) ·
Cardioselective (β1) + vasodilator (1) ·
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Anticoagulants|Anticoagulant]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] (1) ·
[[:Category:DOACs|Direct oral anticoagulant (DOAC)]] (1)
None (1) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
5 mg daily (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1)
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1) ·
~90% (low first-pass) (1)
None (1) ·
Category C (2) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.

